

Oncology Today with Dr Neil Love: Optimal Management of Hodgkin Lymphoma in Younger and Older Patients (Video Presentation)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. On the basis of clinical efficacy data from the Phase III ECHELON-1 study, which of the following regimens would be most appropriate for a patient with previously untreated Stage IV classical Hodgkin lymphoma (HL)?

 - a. Brentuximab vedotin monotherapy
 - b. Brentuximab vedotin and ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine)
 - c. Brentuximab vedotin and AVD
2. Approximately what proportion of patients with HL are older than 60?

 - a. 10%
 - b. 20%
 - c. 30%
 - d. 40%
3. Which of the following combination therapies yielded a superior complete response rate in the Phase I study evaluating brentuximab vedotin (BV) with nivolumab and/or ipilimumab for classical HL?

 - a. BV/ipilimumab
 - b. BV/nivolumab
 - c. BV/nivolumab/ipilimumab
4. Which of the following drug types best describes the novel agent camidanlumab tesirine for relapsed/refractory HL?

 - a. Bispecific antibody
 - b. PBD (pyrrolobenzodiazepine)-based antibody-drug conjugate
 - c. Anthracycline-based antibody-drug conjugate
 - d. Thienoindeole-based antibody-drug conjugate